|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A significant (p ≤ 0.05) correlation between SUV<sub>max</sub> in PSMA-positive liver metastases and both size (ρ<sub>Spearman</sub> = 0.57) of metastases and PSA serum level (ρ<sub>Spearman</sub> = 0.60) was found.
|
31186052 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA ≥ 5.5 ng/mL, locoregional nodal involvement determined by pathology (pN1), prior primary radiation, and prior salvage radiotherapy independently predicted M1 disease (all <i>P</i> < 0.05).
|
31511295 |
2019 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The number of sites (prostate bed, lymph nodes, distant metastases) with positive PSMA uptake was significantly associated with PSA values before imaging (P = 0.0032).
|
29777523 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
[68Ga]PSMA-11, which is the most frequently applied tracer, has shown to detect lymph node metastases, local recurrences, distant metastases and intraprostatic foci with high sensitivity, even at relatively low PSA levels.
|
29869483 |
2018 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PSMA PET/CT scans were performed and patients with PSA persistence (109 patients) or evidence of distant metastases (5 patients) were excluded from this analysis.
|
30002108 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded.
|
30006752 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ga PSMA PET/CT done in view of increased PSA levels and clinically suspicious hard lesion in prostate showed primary lesion in left side of prostate with metastases to the right temporal bone.
|
28045729 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed the impact of salvage extended lymph node dissection (sLND) on cancer control in patients with rising PSA and lymph node (LN) metastases.
|
27824042 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty (13%) patients received guideline-directed PSA screening, 5/155 (3%) patients presented with metastases prior to age 55 with their first PSA, and 130/155 (84%) had their first PSA after age 55, of which 122/130 (94%) had metastasis at the time of diagnosis.
|
28338310 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA progression and metastases were assessed in cohort 1.
|
28470414 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
An interesting dichotomy for CHD8 was observed within primary cancers, with higher nuclear protein expression associated with adverse clinical outcomes including extracapsular extension (P = .007), presence of metastases (P = .025) and worse PSA-recurrence free survival (P = .048).
|
25499215 |
2014 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
MTC02 expression was associated with advanced pathological tumor stage, high Gleason score, nodal metastases (p < 0.0001 each), positive surgical margins (p = 0.0005), and early PSA recurrence (p < 0.0001) if all cancers were jointly analyzed.
|
24261794 |
2013 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite slow PSA rise post surgery in three of these patients, none developed metastases.
|
24052127 |
2013 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA recurrence in 76 patients who underwent radical prostatectomy and survival in 59 patients with metastases at diagnosis were analyzed to evaluate the influence of Mel-18 expression in cancer progression using Kaplan-Meier analysis and multivariate Cox regression analysis.
|
19395284 |
2011 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The miR-34c expression was found to inversely correlate to aggressiveness of the tumor, WHO grade, PSA levels and occurrence of metastases.
|
21351256 |
2010 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The risk of prostate cancer development, the PSA level and tumor metastasis may be associated with genetic variation in the ACE I/D genotypes which may be used as an important biomarker for further studies.
|
17465223 |
2007 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Radical prostatectomy specimens and tissue microarrays from transurethral resections and metastases were analyzed for CRISP-3 and PSA by immunohistochemistry.
|
16388501 |
2006 |